Utilize physiologically relevant 3D tumor models engineered for I-O applications
Immuno-oncology, the activation of the patient’s immune response to recognize and selectively kill tumor cells, is a rapidly advancing field of cancer biology. Clinical success in achieving complete remission or an increase in long-term disease-free survival in several cancers has intensified the pursuit of cancer immunotherapies. 3D InSight™ Tumor Microtissues are an especially conducive ex vivo platform (1) for testing the ability of activated immune cell components to effectively penetrate and mediate tumor-specific cell killing in an environment that more closely reflects the in vivo tumor.
Evaluate the enhancement of immune cell infiltration following compound treatment
Immune-mediated Tumor Cell Killing
Assess the effectiveness of immune-therapeutic strategies ex vivo
Assess penetration of antibodies and engineered antibody fragments in vitro